Get the Stockscreener App
19.67
2.39%
0.46
After Hours:
19.67
Dyne Therapeutics Inc stock is traded at $19.67, with a volume of 2.15M.
It is up +2.39% in the last 24 hours and up +12.02% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease being treated, a linker, and an antigen-binding fragment that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$19.21
Open:
$19.25
24h Volume:
2.15M
Relative Volume:
1.00
Market Cap:
$3.25B
Revenue:
-
Net Income/Loss:
$-446.21M
P/E Ratio:
-5.5512
EPS:
-3.5434
Net Cash Flow:
$-423.92M
1W Performance:
-1.55%
1M Performance:
+12.02%
6M Performance:
+20.31%
1Y Performance:
+98.49%
1-Day Range:
$19.04
$20.02
1-Week Range:
$19.04
$20.99
52-Week Range:
$8.06
$25.00
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
19.67 | 3.17B | 0 | -446.21M | -423.92M | -3.5434 |
VRTX
Vertex Pharmaceuticals Inc
|
437.67 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.58 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
793.22 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
310.58 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.41 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-25-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Atlas Venture funds sell Dyne (DYN) shares under 10b5-1 plan - Stock Titan
Dyne therapeutics director Dirk Kersten sells $6.8m in shares By Investing.com - Investing.com Australia
Dyne therapeutics director Dirk Kersten sells $6.8m in shares - Investing.com
DYN (Nasdaq) Form 144: Atlas Venture groups report proposed sales totaling tens of thousands of shares - Stock Titan
Atlas Venture affiliates sell shares of DYN (Nasdaq: DYN) in Rule 144 notices - Stock Titan
Atlas Venture sells DYN stock (Nasdaq: DYN) — 142,571-share entry listed - Stock Titan
Atlas Venture entities sell DYN shares (NASDAQ: DYN) under Form 144 disclosure - Stock Titan
Director-linked fund trims 337K Dyne Therapeutics (DYN) shares under 10b5-1 plan - Stock Titan
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Dyne Therapeutics: De-Risked DMD Opportunity, Pivotal DM1 Readout, and Emerging M&A Appeal Support Buy Rating - TipRanks
H.C. Wainwright reiterates Dyne Therapeutics stock rating at buy By Investing.com - Investing.com Canada
[144] Dyne Therapeutics, Inc. SEC Filing - Stock Titan
The Technical Signals Behind (DYN) That Institutions Follow - Stock Traders Daily
Dyne (DYN) Stock: Next Week (Technical Weakness) 2026-04-20Most Discussed Stocks - Xã Vĩnh Công
[Form 4] Dyne Therapeutics, Inc. Insider Trading Activity - Stock Titan
Dyne Therapeutics Advances Pivotal DYNE-101 Trial in Myotonic Dystrophy Type 1 - TipRanks
DYN SEC FilingsDyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Could Dyne Therapeutics’ (DYN) AMCP Spotlight Reveal How New FDA Leadership May Shape Its Pipeline? - Yahoo Finance
Is It Too Late To Consider Dyne Therapeutics (DYN) After A 152% One‑Year Surge? - simplywall.st
Potential Leadership Change at FDA Could Affect Dyne Therapeutics (DYN) - GuruFocus
Portfolio Shifts: Is Dyne Therapeutics Inc being accumulated by smart money2026 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Breakouts Watch: Will Dyne Therapeutics Inc benefit from government policy2026 Review & Growth Focused Stock Reports - baoquankhu1.vn
Chipmakers Recap: Is Dyne Therapeutics Inc gaining market share2026 Price Targets & Fast Exit/Entry Strategy Plans - baoquankhu1.vn
Travel Stocks: Is now the right time to enter Dyne Therapeutics IncIPO Watch & Safe Capital Growth Plans - baoquankhu1.vn
Dyne Therapeutics (NASDAQ: DYN) asks shareholders to approve 400M-cap increase - Stock Titan
Fundamentals Check: Is Dyne Therapeutics Inc gaining market share2026 Dividend Review & Real-Time Buy Signal Notifications - baoquankhu1.vn
Precision Trading with Dyne Therapeutics Inc. (DYN) Risk Zones - Stock Traders Daily
Darwin Wealth Management LLC Sells 58,250 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Signal Recap: Is Dyne Therapeutics Inc gaining market shareGap Down & Daily Volume Surge Signals - baoquankhu1.vn
DYN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Will Dyne Therapeutics Inc benefit from green energy policiesMarket Activity Recap & Fast Gain Stock Tips - baoquankhu1.vn
Dyne Therapeutics (DYN) shares key details for pivotal drugs - MSN
Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed - Stock Titan
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders - Sahm
Dyne Therapeutics, Inc. (DYN) stock price, news, quote and history - Yahoo Finance UK
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines - Sahm
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN) - GuruFocus
Director at Dyne Therapeutics (DYN) adds 2,000 common shares - Stock Titan
Dyne uses AMCP to make its case for DMD and DM1 patient access - Stock Titan
Fed Watch: Can Dyne Therapeutics Inc disrupt its industryMarket Risk Analysis & Daily Volume Surge Trade Alerts - baoquankhu1.vn
DYN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Technical Reactions to DYN Trends in Macro Strategies - Stock Traders Daily
Bullish analyst opinion on Dyne (DYNE) follows rare disease drug progress in Japan - MSN
Is Dyne Therapeutics Inc a turnaround storyPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Biotech Price Target Raised on Strong FSHD & DM1 siRNA Data - Streetwise Reports
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4 - Insider Monkey
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership - stocktitan.net
Rare Disease Biotech Sell Rating Maintained: Early Clinical Data Fails to Offset Flagship Drug Revenue Decline - Streetwise Reports
Raymond James reiterates Strong Buy on Dyne Therapeutics stock By Investing.com - Investing.com Canada
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
2.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):